It was previously shown that despite PERK activation and eIF2α phosphorylation in the liver of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), downstream effectors such as CHOP remain inactive [40]. Here, EIF2AK3 is linked to metabolic dysfunction-associated steatohepatitis.